Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are a bunch of TROLLS!
Nothing but a lot of smoke.
Dewey, Cheatem and Howe, L.L.P.
It's coming. Patience.
We need to fill the gap at $1.50 and then we should take off from there. Great time to be a buyer. Fall will be a prosperous season!
It was on one of their PowerPoint slides yesterday during their presentation. Should be posted on their website now for review.
It was referring to Overall Response Rate.
It means they have an ORR. Not a bad thing.
ORR = 27%
Significant news is on the way when volume picks up. There is always a leak and this stock has run before news many times before. I would plow money into this once the volume upticks. Buy on the way up and forget calling the bottom. I am hoping for an update on cohort 3 & 4 before the end of May. I think this will be the next catalyst to move us into the upper $2 range once again.
Chirp.....Chirp.....Chirp
Quiet before the storm!
Added some cheap shares Monday. I am going to continue accumulation into the beginning of June. Looking forward to the info presented Thursday after the market closes. Something solid is going to happen.
Nice foundation of results. Great strategy so far on rationing cash. Happy to see key players getting stock. Haven't seen a P&D strategy at all, but it is still early! I'm buying on Monday as I see a big jump next week. Maybe I will get it right for a change.
It's coming.
Lol, I love the AH action with the nonexistent volume! Nonetheless, this stock seems to run when insider info leaks. I hope we are going to have another leak with the impending releases. Not sure if it is going to fill the gap, but I am currently betting on it. Also positioned if it is ready for the next run. Revenue anybody?
We've got some interesting news on the horizon. UW, Pierre Fabre, cohort 3 and cohort 4 updates. Monday will be interesting to see if we have hit bottom.
Manipulation goes both ways. I would prefer to be on the winning team. Upping the authorized shares is a necessary step. If the CEO and directors avoid greediness then we should be okay. Further dilution without results will be penal. Lean and mean is great, but you have to crack a few eggs to make an omelet.
I hope these guys make millions on their stock. They have skin in the game!
Nice to see that they are stocking the shelves. Not aware of too many professionals who board a sinking ship.
Very happy with the move to name a CMO. I think they addressed a major weakness moving forward. Just hoping we can avoid significant dilution prior to any major Phase II announcements.
Great time to be a buyer.
Next month my shares shift to LTCG. We are going on a ride soon!
Imminent news next week per the CEO. Should be a good run before the shorts pounce. Unfortunately, short of a licensing deal or buyout, we are still quite a few months away from shaking the shorts. They are legally able to manipulate this stock and have done it well. I hope I'm still around when they get hammered.
We will get a run before the end of the month. Take the dough and wait for the pull back to get cheap shares. Still six months out for anything significant. IMHO
I am tempted to dump my entire holding on a run just to wait for the next pull back.
Hmmm.
Oops, today!
Let's see if we can shake the shorts tomorrow. I digested every bit of the Roth presentation yesterday and I am comfortable in my long position. Nonetheless, I will still play the trend with smaller blocks. Almost like a time machine.
Off to Cabo! GLTA
We just won't shake the shorts until we get something on the revenue side or spectacular Phase II results. This stock makes the same moves at different ranges every time there is news.
Phospholipid ether. This is what carries the linker and the drug. It enters the cell through the lipid raft microdomains and delivers the payload directly into the cell.
The PLE has a high affinity to cancer cells due to the higher concentration of lipids in the cell wall of these cells. This is the entire premise of how they are able to target cancer cells versus healthy cells.
I would guess from the information that I have been able to review that the PLE is attracted at a much higher rate to the high density of phospholipids on the cell wall of the cancer cells. I believe that this attraction more than likely limits the interaction with healthy thyroid cells as the uptake is primarily done by the cancer cells.
I am assuming that the same precautions are needed by patients to deal with the gamma rays from the compound. These precautions seem to be fairly routine and do not lead to significant adverse effects. I am looking forward to much more information from Phase II. In theory, it just makes sense.
I don't see UW in this deep with the company if it were a P&D. This is Caruso's first appointment as a CEO and I have no doubt that there were some bumps in the road at the beginning. Overall, I like the current focus as it is moving the company rapidly towards revenue or some sort of sale.
IMHO
“The problem remains, how do you target, how do you kill the cancer cell while sparing normal cells?” Mukherjee replied. “That was a puzzle in 1920. It was a puzzle in 1970. It’s a puzzle in 2017.”
“But you have more tools now.”
“Many, many more tools.”
CLRB will be one of those tools.
Shorts are starting to develop T-Rex arms.
Curious to see what their burn rate is during conference call next week.
As of the end of 2016 UW held just over 600,000 shares.
When acquiring a business the last thing I want to acquire with the business is a partner. Their move with UW cleans up the path. I don't think they made the move without at least a few phone calls from big pharma.
CLRB holds all the cards as long as the results meet expectations. They can just let the process ride to the finish line. Nonetheless, I think the CEO will pull the trigger when the right offer hits the table.
The right price should be at least $15 per share. I think we will know in the next six months.
While the company has always maintained the rights to develop and commercialize CLR 131 for multiple myeloma, the execution of this licensing agreement provides the company with exclusive rights to the development and commercialization of the compound in multiple myeloma. As a result of this agreement, the company has now consolidated its control of the multiple myeloma indication, while continuing to maintain complete control for all other therapeutic uses of CLR 131.
Another strong move towards acquisition.
CNCE was just acquired for a single CF drug. It went for 160M. Obviously, as they progress into phase II with solid results then the value of the company progressively increases. If I'm the CEO and I get an early offer for the stock then I am going to be asking for compensation for a whole lot of blue sky including IP.
If I were confident in the results as the current CEO seems to be then I wouldn't let this company go for less than 150M. I would put a range on a buyout from early to midway in phase II at 50M-150M. Therefore, I believe that the company would be bought out at of share price ranging anywhere from $5-$15 depending how deep they are into phase II. I find it highly unlikely that the company will not be acquired if they have favorable Phase II results.
Gilead is looking to improve their oncology portfolio and I think they are a perfect match. KITE has made a strong move with their immune based therapies, but as stated earlier they have some significant drawbacks. Therefore, I think CLRB is the perfect answer to KITE, thus highly attractive to big pharma. I hope they both win.
Total shot in the dark, but I am always conservative with estimates and I think these numbers could be blown away with positive results. I have parked a chuck of stock for the long run and hope it turns out well. Nonetheless, this stock has some clear patterns and I will continue to buy and sell smaller lots.
There are some subtly signs present in relation to the company's recent behavior that leads me to conclude that they are actively engaged in discussions to be acquired.
On the other hand, my gut is screaming at me that an acquisition is imminent within the next six to eight weeks.
Purely speculation on my part. Perhaps wishful thinking. Nonetheless, the steadfast and committed longs will be rewarded, IMHO.
I have pondered the same thought and have come to a completely different conclusion.
For KITE, there is no doubt that there is a great outcome on one end and a completely different outcome on the other. Regardless, the stats are very impressive so far, but like CLRB, they need more time to exhibit the Objective Response Rate along with the AE profile and the PFS numbers.
All things being equal, the main difference is the massive cost associated with the fabrication of a targeted treatment for each patient based on their own immune cells that are modified to fight the cancer.
I hope they both have major breakthroughs that solve the dreaded disease that they are targeting. Nonetheless, as an investor, I am confident that they both will thrive with their therapies if they get FDA approval. At the end of the day, cancer patients need options.
Please elaborate.
To support an earlier post in relation to Glilead please take a look at the article through the link. Anyone on this board will recognize the background of the guy referenced in the article as it relates to CLRB.
http://www.reuters.com/article/us-gilead-sciences-novartis-idUSKBN14O13T
The shorts are eventually going to get their hand caught in the cookie jar. They like to prey on this stock whenever there is news.
Hopefully, we can rise incrementally until the next release and break through and hold new levels with Phase II results coming in the near future.
Skepticism is healthy. Idealism is driven by want versus need. SoW is frankly doing nothing for this board. You either believe in the science and the game plan from the CEO or you don't. Short the stock; I won't!!!
Orphan designation for CLR-131?